In this study, the more favorable HER1-targeting characteristics of 86Y- CHX-A’’-DTPA-panitumumab than 86Y- CHX-A’’-DTPA-cetuximab for non-invasive staging and assessment of the HER1 status of MM has been demonstrated. This evidence concerns the gene EGFR and Miyoshi myopathy.